The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: October Scorecard Number of Signals 24 Percent Correct – Prev Close to 5-day Peak 96% Avg Increase – Next open to 5-day Peak 12% Other stats: Number of signals over $10/share 16 Number […]
On December 8, Curis, Inc. (CRIS) presented updated data on its Phase 1 clinical trial of CA-4948, an IRAK4 kinase inhibitor to treat patients with relapsed or refractory (R/R) non-Hodgkin’s lymphoma (NHL). The treatments was well tolerated by patients, and 6 out of 7 experienced anti-cancer activity marked by a decrease in tumor burden. As […]
On December 3, BioCryst Pharmaceuticals, Inc. (BCRX) announced that the FDA approved oral, once-daily ORLADEYO™ (berotralstat) to prevent hereditary angioedema (HAE) attacks in adults and pediatric patients over the age of 12. This is the first oral non-steroidal treatment option for people with HAE. In the Phase 3 clinical trial, ORLADEYO™ significantly reduced HAE attacks […]
The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: October Scorecard Number of Signals 12 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next open to 5-day Peak 8% Other stats: Number of signals over $10/share 7 Number […]
The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: October Scorecard Number of Signals 20 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next open to 5-day Peak 7% Other stats: Number of signals over $10/share 14 Number […]
The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: September Scorecard Number of Signals 12 Percent Correct – Prev Close to 5-day Peak 83% Avg Increase – Next open to 5-day Peak 7% Other stats: Number of signals over $10/share 7 Number […]
On August 8, Spero Therapeutics, Inc. (SPRO) announced positive topline results from its Phase 3 clinical trial. The ADAPT-PO clinical trial evaluates Spero’s oral antibiotic candidate tebipenem HBr for the treatment of complicated urinary tract (cUTI) infection and acute pyelonephritis (AP) in adults. The results showed that Spero’s oral treatment was statistically non-inferior to intravenous […]
The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: August Scorecard Number of Signals 12 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next open to 5-day Peak 6% Other stats: Number of signals over $10/share 7 Number […]
The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: July Scorecard Number of Signals 14 Percent Correct – Prev Close to 5-day Peak 93% Avg Increase – Next open to 5-day Peak 9% Other stats: Number of signals over $10/share 10 Number […]
The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: June Scorecard Number of Signals 24 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next open to 5-day Peak 16% Other stats: Number of signals over $10/share 14 Number […]
Simply register below to get sample signals as they come out!
